Hostname: page-component-68c7f8b79f-lqrcg Total loading time: 0 Render date: 2025-12-15T05:48:58.958Z Has data issue: false hasContentIssue false
  • English
  • Français

Infection Control Measures for Human Parvovirus Bl9 in the Hospital Setting

Published online by Cambridge University Press:  21 June 2016

Stanley J. Naides
Stanley J. Naides*
Affiliation:
Department of Internal Medicine, The University of Iowa College of Medicine, and The Veterans Administration Medical Center, Iowa City, Iowa
*
Division of Rheumatology, GH E400, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242
Get access Rights & Permissions [Opens in a new window]

Extract

A human parvovirus was first discovered serendipitously in blood from asymptomatic donors in 1975' and designated B19 because of the location of the original positive serum in a test panel. Subsequently, the newly discovered virus was determined to be the etiologic agent of most cases of transient aplastic crisis in the setting of chronic hemolytic anemia and of the childhood exanthem erythema infectiosum, or fifth disease. While erythema infectiosum with its classic “slapped-cheek” rash is a childhood illness, “fifth disease” in the adult should not be overlooked. At least 40% of adults lack serological evidence of past human parvovirus B19 infection and are at risk. Adults tend to have a more subtle rash, often lacking the “slapped cheeks,” and tend to have a more severe constitutional, flu-like illness with prominent joint symptoms. While the arthralgia and arthritis of adult “fifth disease” are often self-limiting, they may become chronic and lead to an arthropathy that meets American College of Kheumatology criteria for a diagnosis of rheumatoid arthritis. The arthropathy has been reported to persist up to five years, the longest follow-up now available (A. Wolf; MD, personal communication, August 27, 1987).

Information

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 10 , Issue 7 , July 1989 , pp. 326 - 329
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Cossart, YE. Field, AM, Cant, B, et al: Parvovirus-like particles in human sera. Lancet. 1975;1:72–73.Google Scholar
2. Pattison, JR: The discovery of human parvoviruses, in Pattison, IR (ed): Parvoviruses and Human Disease. Boca Raton, Fla, CRC Press, 1988, pp 2–4.Google Scholar
3. Pattison, JR, Jones, SE, Hodgson, J, et al: Parvovirus infet tions and hypoplastic crisis in sickle-cell anemia (letter). Lancet. 1981;1:664–665.Google Scholar
4. Sergeant, GR, Topley, JM, Mason, K, et al: Outbreak of aplastic crises in sickle cell anemia associated with parvovirus-like agent. Lancet. 1981;2:595–597.Google Scholar
5. Rao, KRP, Patel, AR, Anderson, MJ, et al: Infection with parvovirus-like virus and aplastic crisis in chronic hemolytic anemia. Ann Intern Med. 1983;98:930–932.Google Scholar
6. Dyncan, JR, Potter, CG, Cappellini, MD, et al: Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency. Lancet. 1983;2:14–16.Google Scholar
7. Green, DH. Bellingham, AJ, Anderson, MJ: Parvovirus infection in a family associated with aplastic crisis in an affected sibling pair with hereditary spherocytosis. J Clin Pathol 1984;37:1144–1146.Google Scholar
8. Davidson, RJ. Brown, T, Wiseman, D: Human parvovirus infection and aplastic crisis in hereditary spherocytosis, J Infect 1984;9:298–300.Google Scholar
9. Kelleher, JF Jr., Luban, NLC, Cohen, BJ, et al: Human serum parvovirus as the cause of aplastic crisis in sickle cell disease. Am J Dis Child. 1984;138:401–403.Google Scholar
10. Lefrere, J-J, Girot, R, Courouce, A-M, et al: Familial human parvovirus infection associated with anemia in siblings with heterozygous ß-thalas-semia. J Infect Dis. 1986;153:977–979.Google Scholar
11. Fsukada, T, Koike, T, Koike, R. et al: Epidemic of aplastic crisisitic patients with hereditary spherocytosis in Japan (letter). Lancet. 1985;1:1401.Google Scholar
12. Lefrere, JJ, Boutrad, P, Courouce, A-M, et al: Familial human parvovit us infections (letter). Lancet. 1985;2:333–334.Google Scholar
13. Bertrand, Y, Lefrere, JJ, Leverger, F, et al: Autoimmune haemolytic anaemia revealed by human parvovirus linked eryihroblastopenia (letter). Lancet. 1985;2:382–383.Google Scholar
14. Summerfield, GP, Wyatt, GP: Human parvovirus infection revealing hereditary spherocytosis (letter). Lancet. 1985;2:1070.Google Scholar
15. Lefrere, J-J, Courouce, A-M, Girot, R, et al: Human parvovirus and thalassemia. J Infect 1986;13:45–49.Google Scholar
16. Saarinen, UM, Chorba, FL, Tattersall, P, et al: Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood. 1086;67:1411–1417.Google Scholar
17. West, NC:, Meigh, RE, Mackie, M, et al: Parvovirus infection associated with aplastic crisis in a patient with HEMPAS. J Clin Pathol 1986;39:1019–1020.Google Scholar
18. Lefrere, J-J. Courouce, A-M, Bertrand, Y, et al: Human parvovirus and aplastic crisis in chronic hemolytic anemias: A study of 24 observations. Am J Hematol. 1986;23:271–275.Google Scholar
19. Anderson, MJ. Jones, SE, Fisher-Hoch, SP, et al: Human parvovirus, the cause of erythema infectiosum (fifth disease) (letter). Lancet. 1983;1:1378.Google Scholar
20. Okabe, N, Koboyashi, S, Tutsuzawa, O. et al: Detection of antibodies to human parvovirus in erythema infectiosum (fifth disease). Arch Dis Child. 1984;59:1016–1019.Google Scholar
21. Plummer, FA, Hammond, GW, Forward, K, et al: An erythema infec-tiosum-like illness caused by human parvovirus infection. N Engl J Med. 1985;313:74–79.Google Scholar
22. Nunoue, T. Okochi, K. Mortimer, PP, et al: Human parvovirus (B19) and erythema infectiosum. J Pediatr 1985;107:3X–40.Google Scholar
23. Chorba, T, Coccia, P, Holman, RC, et al: The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis. 1986;154:383–393.Google Scholar
24. Ager, EA, Chin, TDY, Poland, JD: Epidemic erythema infectiosum. N Engl J Med. 1966;275:1326–1331.Google Scholar
25. Brandrup, F, Larsen, PO: Erythema infectiosum (fifth disease) (letter), Br Med J. 1976;2:47–48.Google Scholar
26. Lauer, BA, MacCormack, JN, Wiliert, C: Erythema infectiosum. An elementary school outbreak. Am J Dis Child. 1976;130:252–254.Google Scholar
27. Schneerson, JM. Mortimer, PT, Vandervelde, EM: Febrile illness due to a parvovirus. Br Med J. 1980;2:1580.Google Scholar
28. Hidano, A, Ogihara, Y. Oryu, E, et al: Epidemiology, of an outbreak of erythema infectiosum in Tokyo. Int J Dermatol. 1983;22:161–164.Google Scholar
29. Andrew, M, Martin, RWY, Duff, AR, et al: Fifth disease: Report ot an outbreak. J R Coll Gen Pract. 1984;34:573–574.Google Scholar
30. Tuckerman, JG, Brown, T, Cohen, BJ: Erythema infectiosum in a village primary school; clinical and virological studies. J R Coll Gen Pract. 1986;36:267–270.Google Scholar
31. Rollands, S: Arthralgia from parvovirus infection. J R Coll Gen Pract. 1986;36:288–289.Google Scholar
32. Anderson, MJ: The emerging story of a human parvovirus-like agent. J Hyg. 1982;89:1–8 Google Scholar
33. Cohen, BJ, Mortimer, PP. Pereira, MS: Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). Journal of Hygiene. 1983;91:113–130.Google Scholar
34. Courouce, AM, Ferchal, F, Morinet, F, et al: Human parvovirus infection in France (letter). Lancet. IY84;1:160.Google Scholar
35. Mortimer, PP. Luban, NLC, Kelleher, JF, et al: Transmission of serum parvovirus-like virus by clotting factor concentrates. Lancet. 1983;2:482–484.Google Scholar
36. Paver, WK, Clarke, SKR: Comparison of human fecal and serum parvo-like viruses. J Clin Microbiol. 1976;4:67–70.Google Scholar
37. Naides, SJ, Piette, W, Vcach, LA. et al: Human parvovirus B19-induced vesiculopustular skin eruption. Am J Med. 1988;84:968–972.Google Scholar
3X. Naides, SJ. Field, EH; Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intent Med. 1988;148:2587–2589.Google Scholar
3Y. White, DC, Woolf, AD. Mortimer, PP. et al: Human parvovirus arthropathy. Lancet. 1985;1:419–421,Google Scholar
40. Reid, DM, Reid, TMS, Brown, T, et al: Human parvovirus-associated arthritis: A clinical and laboratory description. Lancet. 1985;1:422–425.Google Scholar
41. Arnett, FC. Edworthy, S, Bloch, DA, et al: The 1987 revised ARA criteria for rheumatoid arthritis (RA) (abstract). Arthritis Rheum. 19X7;30:S17.Google Scholar
42. Brown, T, Anand, A, Ritchie, LD et al: Intrauterine parvovirus infection associated with hydrops fetalis (letter). Lancet. 1984;2:1033–1034.Google Scholar
43. Brown, T, Ritchie, LD: Infection with parvovirus during pregnancy (letter). Br Med J. 1985;290:559–560.Google Scholar
44. Gray, ES, Anand, A, Brown, T: Parvovirus infections in pregnancy (letter). Lancet. 1986;1:208.Google Scholar
45. Anand, A. Gray, ES. Brown, T. et al: Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316:183–186.Google Scholar
46. Woernle, CH, Anderson, LJ, Tattersall, P. et al: Human parvovirus B19 infection during pregnancy. J Infect Dis. 1987;156:17–20.Google Scholar
47. Naides, SJ. Guthbertson, G, Murray, JC, et al: Neonatal sequelae of parvovirus B19 infection utero (abstract). Proceedings, Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif, October 23-26, 1988.Google Scholar
48. Carrington, D, Gilmore, DH, Whittle, MJ, et al: Maternal serum A-fetoprotein—A marker of fetal aplastic crisis during intrauterine human parvovirus infection. Lancet. 1987;1:433–435.Google Scholar
49. Porter, HJ. Khong, TY, Evans, MF, et al: Parvovirus as a cause of hydrops letalis: Detection by in situ DNA hybridization. J Clin Pathol. 1988;41:381–383.Google Scholar
50. Franciosi, RA, Tattersall, P: Fetal infection with human parvovirus B19. Hum Pathol. 1988;19:489–491.Google Scholar
51. PHLS Working Parry on Fifth Disease: Study of human parvovirus (B19) infection in pregnancy. Communicable Disease Reports 1987;22(5):20.Google Scholar
52. Naides, SJ: Erythema infectiosum (fifth disease) occ urrence in Iowa. Am J Public Health. 1988;78:1230–1231.Google Scholar
53. Lefrere, JJ, Bourgeois, H: Human parvovirus associated with erythro-blastopenia in iron deficiency anemia. J Clin Pathol. 1986;39:1277–1278.Google Scholar
54. Van Horn, DK, Mortimer, PP, Young, N, et al: Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol. 1986;8:235–239.Google Scholar
55. Kurtzman, GJ, Ozawa, K, Cohen, B, et al: Chronic hone marrow failure due to persistent B19 parwvirus infection. N Engl J Med. 1987;317:287–294.Google Scholar
56. Kurtzman, GJ, Cohen, B, Meyers, P, et al: Persistent B19 parvovirus infection as a cause of severe anaemia in children with acute lymphocytic leukemia. Lancet. 198X;2: 1159–1162.Google Scholar
57. Coulombel, L, Morinet, F, Mielot, F, et al: Parvovirus infection, leukemia, and immunodeficiencv (letter). Lancet. 1989;1:101–102.Google Scholar
5X. Davidson, JE, Gibson, B, Gibson, A, et al: Parvovirus infection, leukemia, and immunodeficiency (letter). Lancet. 1989;1:102.Google Scholar
59. Graeve, JLA, de Alarcon, P, Naides, SJ: Parvovirus B19 infection in patients receiving cancer chemotherapy: The expanding spectrum of disease. Am J Pediatr Hematol Oncol. 1989;to he published.Google Scholar
60. Naides, SJ: Human parvovirus infection: Initial clinical experience (abstract). Arthritis Rheum 1988;31:S36.Google Scholar
61. Naides, SJ, Weiner, CP: Antenatal diagnosis and palliative treatment of non-immune hydrops fetalis secondary to fetal parvovirus BIY infection. Prenatal Diagnosis 1989;9:105–114.Google Scholar
62. Evans, JPM, Rossiter, MA, Kumaran, TO, et al: Human parvovirus aplasia;case due to cross infection in a ward. Br Med J. 1984;288:681.Google Scholar
63. Peter, G (ed): Report of the Committee on Infectious Diseases, ed 21. Elk Grove Village, Ill, American Academy of Pediatrics. 1988, p 311.Google Scholar
64. Centers for Disease Control: Risks associated with human parvovirus B19 infection. MMWR. 1989;261:81–97.Google Scholar
65. Naides, SJ, Bell, LM, Stoffman, P, et al: Two separate outbreaks of human parvovirus B19 infection among the hospital staff of a children's hospital (abstract). Arthritis Rheum. 1989;32:S98.Google Scholar
66. Anderson, MJ. Higgins, PG, Davis, LR, et al: Experimental parvoviral infection in humans. J Infect Dis. 1985;152:257–265.Google Scholar
67. Joseph, PR: Incubation period of fifth disease (letter). Lancet. 1986;2:1390–1391.Google Scholar
68. Morgan-Capner, P, Wright, J, Longley, JP, et al: Sex ratio in outbreaks of parvovirus infection (letter). Lancet. 1987;2:98.Google Scholar
69. Weiland, HT, Vermey-Keers, C, Salimans, MMM, et al: Parvovirus B19 associated with fetal abnormality (letter). Lancet. 1987;1:682–683.Google Scholar
70. Clewley, JP, Cohen, BJ, Field, AM: Detection of parvovirus B19 DNA, antigen, and particles in the human fetus. J Med Virol. 1987;23:367–376.Google Scholar
71. Anderson, LJ, Tsou, C, Parker, RA, et al: Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986;24:522–526.Google Scholar